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Abstract
Background: Acid sphingomyelinase (ASM) is a key regulator of ceramide-dependent 
signalling pathways. Among others, activation of ASM can be induced by CD95 or cytokine 
signalling and by cellular stress resulting from inflammation or infection. Increased ASM activity 
was observed in a variety of human diseases including inflammatory and neuropsychiatric 
disorders. We hypothesized that basal ASM activity might influence the susceptibility for 
common human diseases. Methods: The general health condition of 100 young people was 
assessed using a questionnaire. The ASM polymorphism rs1050239 (c.1522G>A; encoding 
p.G508R) was determined from genomic DNA. Activities of secretory (S-) and lysosomal 
(L-) ASM were measured in blood plasma and peripheral blood cells respectively. Results: 
The polymorphism rs1050239 was significantly associated with self-reported allergy 
(p=4.68×10-4; adjusted p-value for multiple testing 0.007). Allergy was more prevalent in carriers 
of the minor A allele compared to non-carriers (p=0.00015; odds ratio=6.5, 95% CI 2.15–21.7). 
S-ASM activity was significantly associated with rs1050239 (p=5.3×10-7) and decreased with 
the number of A alleles in a gene-dosage dependent manner. In allergic patients, S-ASM 
activity was moderately decreased (p=0.034). L-ASM activity was significantly lower in subjects 
homozygous for the minor A allele (p=0.025) but not different between allergic and non-
allergic subjects (p=0.318). Conclusion: Our analysis provides evidence for an involvement 
of ASM in the pathophysiology of allergy, which is in line with previous reports addressing 
the role of sphingolipids in this disorder. Further studies should clarify the mechanism linking 
rs1050239 to allergy. The ASM pathway might be useful for predicting allergic disposition and 
disease course and as a therapeutic target.
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Acid sphingomyelinase (ASM, EC 3.1.4.12) catalyses the hydrolysis of sphingomyelin, 
a major lipid component of cellular membranes, into ceramide and phosphorylcholin. 
Ceramide and its further metabolites sphingosine and sphingosine-1-phosphate act as 
bioactive molecules and play roles in the regulation of cell growth, cell death, senescence, 
adhesion, migration, inflammation, angiogenesis and intracellular trafficking [reviewed in 
1, 2]. 
Ceramide-generating enzymes such as ASM have gained attention as key regulators of 
ceramide-dependent signalling pathways. Activation of ASM and a concomitant increase in 
ceramide concentrations can be induced by the stimulation of various receptors, including 
CD95 or those for tumor necrosis factor (TNF)-α, interleukin (IL)-1β or platelet-activating 
factor, or by cellular stress such as inflammation, infection, ischemia, radiation, oxidative 
stress, chemotherapeutic agents or cell wounding [3-12]. Increased ASM activity was 
observed in several human diseases such as chronic heart failure, type 2 diabetes, sepsis, 
peritonitis, hepatitis, hemophagocytic lymphohistiocytosis, antineutrophil cytoplasmic 
antibody-associated primary systemic vasculitis, neurodegeneration, depression and alcohol 
abuse [13-23]. A variety of small organic, drug-like compounds that functionally inhibit 
ASM are used in the therapy of human diseases [24-26]. In various experimental mouse 
models, such as lipopolysaccharide (LPS)-, TNF-α- or Cu2+-induced liver damage or alcohol-
induced steatosis, genetic deficiency or pharmacological inhibition of ASM was associated 
with beneficial outcome [27-30]. A reduction in ASM activity also normalized pulmonary 
ceramide levels and infection susceptibility in a mouse model of cystic fibrosis [30, 31]. Taken 
together, these reports suggest that ASM hyperfunction could be a risk factor for human 
health. However, ASM-dependent sphingomyelin degradation is an essential cellular process. 
An inherited deficiency of ASM causes the lysosomal storage disorder Niemann-Pick disease 
[32], which is characterized by the accumulation of sphingomyelin in the endolysosomal 
compartment. Patients often present hepatosplenomegaly, respiratory complications, 
atherogenic lipid profiles and sometimes progressive neurodegeneration [33]. In addition, 
ASM plays a pivotal role in the host defense against pathogens and metastasising cancer [8, 
34, 35]. Thus, a balanced activity of ASM seems to be beneficial to maintain human health. 
ASM is a glycoprotein located in the endolysosomal compartment, in secretory 
vesicles and at the outer leaflet of the plasma membrane [36]. The enzyme is also present 
in various human body fluids including blood serum [37, 38]. Despite the broad evidence 
for an involvement of ASM in human diseases, little is known about the regulation of the 
basal ASM activity and its importance for human health. We hypothesized that the individual 
ASM activity is a constitutive trait that, even within the normal range, influences context-
dependent ceramide-induced signalling pathways, thereby altering susceptibility for human 
diseases. For the analysis, we defined individual ASM constitution as the secretory (S-) ASM 
activity from blood plasma, the lysosomal (L-) ASM activity from peripheral blood cells, and 
the genotype of the common ASM polymorphism rs1050239. These data were compared 
with the prevalence of common human diseases in a sample of 100 young participants. Our 
analysis revealed evidence for an genetic association of ASM with allergy. 
Materials and Methods
Study sample
The study sample consisted of 100 young people that had participated in the GENES study [39, 40]. 
Study subjects were free of somatic diseases potentially affecting brain function, past or current mental 
disorders, regular intake of drugs (except hormonal contraceptives), abuse of mind-altering substances 
(except moderate consumption of alcohol) and were not pregnant. Participants in addition filled out a 
general health questionnaire that was sent to them one year after the first examination. All participants were 
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signed the Patient Information Protocol and an Informed Consent Statement. The study was conducted in 
accordance with the 2008 Declaration of Helsinki and was approved by the Ethics Committee of the Medical 
Faculty of the Friedrich-Alexander University Erlangen-Nuremberg.
General health survey 
To determine the general health condition of the participants a set of health related questions that 
could be answered by self-assessment were extracted from the literature and compiled into a questionnaire 
by a psychologist specialized in test psychology. The complete questionnaire (http://opus4.kobv.de/opus4-
fau/frontdoor/index/index/docId/4654) covered four aspects of health (protective and risk factors; 
infectious diseases; chronic disorders; current well-being). For the question addressed in this study only the 
parts assessing the prevalence of infectious diseases and chronic disorders were relevant and considered 
for analyses. 
Determination of ASM activity 
S-ASM and L-ASM activities were assessed from blood plasma and peripheral blood mononuclear cells 
respectively, as previously described [21, 22]. 
Genetic analysis 
Genomic DNA was isolated from whole blood using the Gentra Puregene Blood Kit (Qiagen, Hilden, 
Germany) according to the supplier’s protocol. Genotyping of the ASM polymorphism rs1050239 was 
performed using polymerase chain reaction and restriction fragment length polymorphism analysis 
with the forward oligonucleotide 5′-TCCTGGAGTTGGTGGGATAG-3′ and reverse oligonucleotide 
5′-GGTATGTTTGCCTGGGTCAG-3′. The 227 bp PCR product was digested with the restriction enzyme 
NciI (New England Biolabs, Frankfurt am Main, Germany) according to the manufacturer’s protocol. The 
fragments were separated on a 3% agarose gel and visualized using ethidium bromide staining and UV 
light. The PCR product derived from the major G allele (c.1522G; encoding ASM Gly508) was cleaved into 
two fragments (162 and 67 bp), whereas that from the minor A allele (c.1522A; encoding Arg508) was 
not cleaved. Genotyping for each sample was performed twice with 100% confirmation. The distribution 
of genotypes (GG, n=52; GA, n=42; AA, n=6) did not deviate from the Hardy-Weinberg equilibrium (chi-
squared test: p=0.807). 
Statistical analyses 
Statistical analyses were performed with the software package IBM SPSS Statistics 19. Health 
conditions were analyzed as nominal-scaled variables with two levels (infections at least once a year: “yes” 
or “no”; complications during the course of infections: “yes” or “no”; presence of chronic diseases: “yes” or 
“no”). The genetic variable rs1050239 was used ordinally, scaled with three levels represented by the three 
genotypes GG, GA and AA. S- and L-ASM activities were used as metric continuous variables. Associations 
were analyzed by ANOVA and significant results were tested for confounding effects of sex and age. All other 
tests used are given with the results. A p-value ≤ 0.05 was considered to indicate significance. Adjustment 
for multiple comparisons was conducted by Bonferroni correction. 
Results
To test the hypothesis that basal ASM activity relates to the susceptibility for common 
human diseases, we assessed the general health condition of 100 young people (33 males, 
67 females; mean age ± SD: 24.1 ± 3.1 years) using a self-assembled questionnaire (see 
method section). Participants were asked whether they suffer regularly from any of 11 given 
infectious diseases, any of seven given complications accompanying infections or any of 
16 given chronic diseases. Fifteen interrogated health issues (43%) were prevalent in our 
sample with a frequency >5% and were selected for further analysis (Table 1). The other 
twenty items (57%) were answered by ≥95% of the participants with the same value and 
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The genetic influence of ASM on the prevalence of common human health issues 
was tested by ANOVA with the respective health issue as dependent variable and the 
polymorphism rs1050239 as independent variable. These analyses revealed a strong 
association of rs1050239 with allergy (one-way ANOVA: F=8.305, df=2, p=4.68×10-4) that 
was not confounded by age or sex (data not shown). The p-value for this association remained 
significant after adjustment for multiple comparison (p=0.007). A detailed analysis revealed 
that the prevalence of allergy was 45% in subjects heterozygous for rs1050239 (19 allergic 
patients out of 42 participants with the genotype GA), 50% in subjects homozygous for the 
minor A allele (3 out of 6), and 12% in subjects homozygous for the major G allele (6 out 
of 52) (Fig. 1A). Therefore, allergy was more prevalent in carriers of the minor A allele of 
rs1050239 compared to non-carriers of this allele (Fisher’s exact test: p value=0.00015; 
odds ratio=6.5, 95% CI 2.15–21.7). 
We next analyzed whether rs1050239 had an influence on the L- or S-ASM activity 
determined from blood cells and blood plasma respectively. The activities of S- and L-ASM 
in our sample did not deviate from a normal distribution with means (±SD) of 1.82 (±0.58) 
nmol/mg/h and 200 (±69) pmol/ml/h respectively (Kolmogorov-Smirnov test: p=0.419 
and 0.471). S-ASM activity was slightly higher in females compared to males (males, n=33: 
180±68 pmol/ml/h; females, n=67: 210±68 pmol/ml/h; t-test: p=0.042), and both S- and 
L-ASM activities correlated modestly with age (L-ASM: Pearson r=0.198, p=0.048; S-ASM: 
r=0.218, p=0.029). The correlation between S- and L-ASM activities was not significant 
(r=0.189, p=0.060). 
Of note, S-ASM activity associated significantly with rs1050239 (one-way ANOVA: 
F=16.845, df=2, p=5.3×10-7) (Fig. 1B). S-ASM activity was highest in subjects with the 
genotype GG (230±66 pmol/ml/h; n=52), intermediate in heterozygous subjects (176±53 
pmol/ml/h; n=42) and lowest in subjects homozygous for the A allele (109±48 pmol/
ml/h; n=6). Post-hoc analysis revealed significant differences between all three genotypes 
(Bonferroni: GG vs. GA: p=1.09×10-4; GG vs. AA: p=2.51×10-5; GA vs AA: p=0.033). The genetic 
effect on S-ASM activity was similar for male and female participants and was not influenced 
by age (data not shown). L-ASM activity was not significantly associated with rs1050239 
Table 1. Association of health issues with the ASM status. Self-reported health-issues with a prevalence 
of >5% in the study sample are shown together with their p-values generated from ANOVA (rs1050239: 
one-way ANOVA; S- and L-ASM activities: multifactorial ANOVA with sex and age as covariates). Significant 
results are indicated in bold. Arrows indicate increased and decreased activity in affected vs. not affected 
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in the genotype comparison (one-way ANOVA: F=2.547, df=2, p=0.084). However, L-ASM 
activity was significantly lower in subjects homozygous for the minor A allele in comparison 
to the two other genotypes (AA: 1.31±0.67 nmol/mg/h, n=6; GG/GA: 1.85±0.56 nmol/mg/h, 
n=94; one-way ANOVA: F=5.146, df=1, p=0.025) (Fig. 1C).  
Given that rs1050239 associated significantly with allergy and ASM activity, we wondered 
whether allergy would also be associated with S- or L-ASM activity. An ANOVA with health 
issues as dependent variable and both S- and L-ASM activities as independent variables 
revealed a significant association of allergy with S-ASM activity that was independent of the 
influence of sex or age (p=0.034) (Table 1). L-ASM activity was not associated with allergy 
(p=0.318). S-ASM activity was decreased by 17% in subjects with allergy compared to not 
affected subjects (allergy: 175±69 pmol/ml/h, n=28; no allergy: 210±67, n=72; Figure 1D). 
Of note, when rs1050239 was considered as a covariate, the association of allergy with S-ASM 
activity was no longer significant (data not shown), indicating that the decreased S-ASM 
activity in allergic participants is due to association with the rs1050239 polymorphism. 
Besides allergy, four additional self-reported health issues were associated either with 
S- or L-ASM activity in our survey (Table 1). However, these diseases did not associate with 
the rs1050239 genetic marker. 
Discussion
Activation of ASM is observed in various experimental settings and in a variety of human 
diseases and is thus considered a promising target for therapeutic intervention [26]. While it 
is widely accepted that ASM is an important regulator of the host response to harmful stress, 
little is known about how the basal ASM activity affects this response and the establishment 
of related diseases. Experimental work using animal models of genetic or pharmacological 
ASM deficiency have provided good evidence that ASM status can affect host susceptibility for 
different diseases [8, 30, 41-44]. However, clear evidences of whether/how ASM responses 
influence disease liability in human are missing. 
Fig. 1. Association of the polymorphism rs1050239 (c.1522G>A) encoding the ASM variant p.G508R with 
self-reported allergy and ASM activity. (A) The prevalence of allergy was higher in carriers of the minor 
A allele compared to non-carriers. (B) The ASM polymorphism rs1050239 was strongly associated with 
S-ASM activity in blood serum. (C) L-ASM activity was lower in subjects homozygous for the minor A allele 
compared to the two other genotypes. (D) Participants diagnosed with allergy (n=28) presented with 
significantly lower S-ASM activity in the blood plasma than people not reporting allergy (n=72). Columns 
represent mean values and error bars standard deviation. ASM, acid sphingomyelinase; L-ASM, lysosomal 
ASM; S-ASM, secretory ASM. Asterisks in panels A–C indicate significant differences compared to genotype 
GG (Bonferroni post hoc: * p-value < 0.05; *** p-value < 0.001), and hashes significant difference compared 
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To address this we developed a general health survey that can be conducted by self-
assessment and which is thus suitable for the screening of larger cohorts. We used the 
survey to quantify the general health condition of 100 study subjects and to determine the 
relationship with the basic ASM constitution. The individual ASM status was characterized 
by the ASM genotype with respect to the polymorphism rs1050239, as well as the S-ASM and 
L-ASM activity from blood plasma and blood cells respectively. 
Using this approach we found evidence that allergy might be genetically linked to 
ASM. Carriers of the minor A allele of rs1050239 reported significantly more often to be 
diagnosed with symptoms of allergy than people homozygous for the G allele. We observed 
no difference in the prevalence of allergy comparing heterozygous subjects with subjects 
homozygous for the minor A allele, suggesting this allele is an allergy risk factor. Rs1050239 
represents the most frequent polymorphism in the coding region of the mature ASM 
enzyme and encodes an exchange at the amino acid position 508. Although the molecular 
consequences of this transition have not been studied in detail, the transition is adjacent to 
a potential phosphorylation site that was reported to be involved in the enzyme’s activation 
and secretion [45, 46]. Due to the replacement of an uncharged glycine residue by a charged 
amino acid, the substitution Gly508>Arg508 might affect the respective phosphorylation 
site recognition motif. Although the clinical significance of rs1050239 has still to be proven, 
carriers of the minor allele were reported to exhibit altered plasma cholesterol concentrations 
and an increase in family history of coronary artery disease [47]. 
Our analysis further revealed that rs1050239 is associated with blood plasma S-ASM 
activity. It can be assumed that this activity mainly reflects the amount of the ASM enzyme 
in the analyzed specimen. In addition, post-translational or conformational modifications 
may change the specific enzymatic activity [46, 48] and thus contribute to the total activity 
determined in the clinical samples. We found that rs1050239 associates with S-ASM activity 
in a gene-dosage dependent manner. Heterozygous subjects displayed intermediate S-ASM 
activity levels, while subjects homozygous for the minor A allele displayed half the activity 
found in subjects homozygous for the major G allele. These results suggest that rs1050239 
might influence the in vivo secretion of ASM through interference with the adjacent 
phosphorylation site. However, it is also possible that the molecular exchange affects protein 
stability and/or activation. Whether rs1050239 also affects L-ASM activity remains unclear. 
Although we observed that L-ASM activity was lowest in the AA genotype group, the p value 
was moderate. Therefore, further studies will be required to determine if rs1050239 affects 
L-ASM. 
Subjects with allergy also presented with decreased S-ASM activity compared to 
participants not affected by allergy. This observation might be attributed to the genetic 
association of the minor A allele with allergy, and does not necessarily imply that decreased 
S-ASM levels are involved in the pathomechanism leading to allergy. Compared to the strong 
genetic association we observed, the association of S-ASM with allergy was only moderate. 
Therefore, the genetic effect of rs1050239 might be mediated by mechanisms other than the 
regulation of S-ASM abundance in the blood. It is also possible that the genetic effect is not 
directly mediated by rs1050239, but by another polymorphism associated with the minor A 
allele, or that the genetic effect is not mediated by ASM. 
An involvement of ASM in allergy and asthma has been previously reported. Stimulation 
of murine mast cells with antigen resulted in increased L-ASM activity [49]. The same study 
demonstrated that genetic deficiency of ASM impairs the antigen-triggered Ca2+ release 
from internal stores, the release of β-hexosaminidase and the antigen-induced migration of 
mast cells. Systemic anaphylaxis assessed by the decline in body temperature was also less 
pronounced in ASM-deficient mice [49]. Clustering of CD40 on B cells, which is involved in 
the signal cascade triggering the class switch to IgE, requires the clustering of CD40 ligand, 
which in turn involves the activation and translocation of ASM to the plasma membrane 
[50]. In a clinical study, increased levels of sphingomyelin and an increased activity of ASM 
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studies revealed increased ceramide levels and a role of the glycosphingolipid pathway in 
airway hyperresponsiveness and asthma [52, 53]. Taken together, these reports imply that 
allergy susceptibility increases with ASM hyperactivity. How this fits together with the 
genetic association of rs1050239 with allergy susceptibility is not clear. To answer this 
question, further studies addressing the cellular consequences of rs1050239, especially 
under challenging conditions such as allergic reaction, are certainly necessary.
In our survey, in addition to allergy other health issues were found to be associated 
with L- or S-ASM activity. For example, decreased S-ASM activity was associated with the 
susceptibility for infections of the lower respiratory tract, which is a common complication 
in patients with Niemann-Pick disease [54, 55]. This might indicate that a low basal ASM 
activity compromises the host defense against bacterial infections. However, the p values of 
the associations we observed were modest and not sufficiently robust to survive multiple 
testing. In addition, there was no association with the ASM genotype, and thus the direction 
of the relationship is unclear. 
Limitations of our study include that it was conducted as a monocentric study with a 
relatively small number of cases, and that the health issues were self-reported without a 
detailed clinical classification. In our analysis, participants diagnosed with allergic asthma, 
hay fever or allergic skin rash were subsumed as allergic patients. The detailed respective 
diagnosis, the current medication or the causative antigen was not assessed by the survey. 
Furthermore, additional allergy types, such as food allergy, were not addressed. Future 
studies involving a detailed medical history will therefore be necessary to verify and to 
specify our findings. 
In summary, we provide evidence that the ASM pathway plays a role in the 
pathophysiology of allergy. This is in agreement with other clinical and preclinical reports 
about the involvement of sphingolipids in the disease. The ASM pathway might be used to 
predict allergic disposition and to define new therapeutic targets. A better understanding of 
the molecular changes associated with the ASM coding variant rs1050239 might give new 
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